Phase 3 IgA Nephropathy (IgAN) Clinical Trials
2 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–2 of 2 trials
Recruiting
Phase 3
Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN
IgA Nephropathy (IgAN)
Haisco Pharmaceutical Group Co., Ltd.370 enrolled1 locationNCT07390123
Recruiting
Phase 3
A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria
IgA Nephropathy (IgAN)
Biocity Biopharmaceutics Co., Ltd.360 enrolled1 locationNCT06819826